✨ Free AI Report
Mustang Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Mustang Bio, Inc.
Company Research

Mustang Bio, Inc.: Business Overview, Financials & Competitive Analysis

Mustang Bio is a clinical-stage biopharmaceutical company focused on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company has partnered with to...

Analyst-debate audio for Mustang Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Mustang Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Early-stage cell therapy platform with legitimate science and partnerships but severe capital constraints and competitive...

Read the full analyst-debate transcript →
Industry Gene Therapy
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 9, 2026
AI-Generated Research
30+ Page Report

Get the Latest Mustang Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Mustang Bio, Inc. Overview

Pro stress-test →

Mustang Bio is a clinical-stage biopharmaceutical company focused on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company has partnered with top medical institutions to advance the development of CAR-T therapies, with MB-106 as its lead clinical candidate.

Strategic Profile

Pro stress-test →

Mustang was founded by Fortress Biotech, Inc. The company operates a licensing and partnership model, acquiring rights to cell and gene therapy technologies and advancing them through clinical development. As of June 2, 2026, Mustang Bio has a market capitalization of $5.77 million, reflecting significant shareholder dilution from its peak, though the company continues advancing multiple clinical programs.

Competitive Landscape

Pro stress-test →

Mustang competes in the cell therapy/CAR-T space against better-capitalized public companies including Gilead Sciences (CAR-T leader), Novartis, Juno Therapeutics/Celgene, and numerous private cell therapy developers. Mustang's clinical-stage status and limited resources place it at a disadvantage relative to established CAR-T manufacturers and larger biotech competitors with proven manufacturing and commercial capabilities.

Industry Context

Mustang Bio, Inc. operates in Gene Therapy.

Key facts

Founded: 2015 · Headquarters: Worcester, US · Employees: N/A · Revenue: N/A · Market cap: $5.77M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Mustang Bio, Inc..

  • Dramatic market cap erosion of 97.75% since 2017 suggests persistent execution challenges or investor skepticism about the pipeline
  • Lead program MB-106 targets large oncology markets (non-Hodgkin lymphoma, chronic lymphocytic leukemia) with Phase I status; regulatory path remains unclear
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Published Q1 2026 quarterly earnings report
  • March 2026Published Q4 2025 annual report
  • +2 moreTrack every material event for Mustang Bio, Inc. as it happens. Explore monitoring →
Get alerted when Mustang Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KymriahFDA-approved CAR-T therapy for B-cell acute lymphoblastic leukemia and lymphoma→YescartaLeading commercial CAR-T platform for relapsed/refractory large B-cell lymphoma→Juno CAR-TCAR-T therapy development and commercialization→Allogene TherapeuticsOff-the-shelf allogeneic CAR-T cell therapies→

Compare Mustang Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Mustang Bio, Inc. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Mustang Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Mustang Bio, Inc. and its top competitor on Cyborg Score”
“What did Mustang Bio, Inc. do this quarter?”
“Is Mustang Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Mustang Bio, Inc. do?+
Mustang Bio is a clinical-stage biopharmaceutical company focused on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company has partnered with to...
What is Mustang Bio, Inc.'s Cyborg Score?+
Mustang Bio, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Mustang Bio, Inc.'s main competitors?+
Named competitors include Kymriah, Yescarta, Juno CAR-T, Allogene Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Mustang Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Mustang Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Mustang Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.